2026 Flu Vaccine Brand Comparison: Ingredients, Origins, and Side Effects of Vaxigrip, Flublok, Sanofi, Sinovac, Abbott, and More

As autumn and winter arrive in Hong Kong, the peak influenza season approaches. Getting vaccinated early is the most effective way to prevent severe illness and hospitalization. Faced with a wide variety of brands and vaccine technologies on the market, how should members of the public choose?

This article provides an objective, comprehensive analysis of mainstream influenza vaccines—including Sanofi, Abbott, Sinovac, and recombinant technologies—covering their ingredients, mechanisms, side effects, and target demographics to help you make an informed and healthy decision.

Why Is an Annual Flu Shot Necessary?

Influenza is caused by influenza viruses. Their surface antigens (Hemagglutinin, HA, and Neuraminidase, NA) are prone to minor "antigenic drift," causing viral strains to mutate continuously from year to year. Every year, the World Health Organization (WHO) convenes international experts to monitor global epidemiological trends and announces the recommended composition of influenza virus vaccines for the Northern Hemisphere each February.
After vaccination, the human immune system requires approximately 2 to 4 weeks to produce sufficient concentrations of neutralizing antibodies. Antibody titers within the body generally decline gradually 6 to 12 months post-vaccination. Consequently, regardless of whether you received a vaccine or contracted influenza during the prior season, receiving the updated seasonal flu vaccine on schedule each year is essential to ensure adequate immune protection.

Overview of Mainstream Flu Vaccine Brands and Manufacturers

Influenza vaccine brands available in Hong Kong and commonly included in the government's Vaccination Subsidy Scheme (VSS) are primarily manufactured by the following major multinational and regional pharmaceutical companies:

1. Sanofi (Sanofi Pasteur)
   
   • Flagship Products: Vaxigrip Tetra (quadrivalent/trivalent) and Flublok (recombinant influenza vaccine).
     
   • Background: One of the world's largest influenza vaccine producers. Widely administered across public and private healthcare facilities, Maternal and Child Health Centres, and Elderly Health Centres throughout Hong Kong, supported by extensive global clinical data and substantial market share.
     
2. Abbott (Abbott Biologicals)
   
   • Flagship Product: Influvac Tetra.
     
   • Background: A century-old global healthcare company originating from Europe (manufactured in the Netherlands). Utilizing subunit purification technology, it is known for low allergenicity and high purity, making it highly regarded by private clinics and pediatricians.
     
3. Sinovac (Sinovac Biotech)
   
   • Flagship Product: Anfluvac.
     
   • Background: A prominent biopharmaceutical manufacturer based in Mainland China, registered and supplied across Hong Kong and Southeast Asia. It offers competitive pricing and is utilized by select non-governmental organizations (NGOs) and private outpatient clinics.
     
4. GlaxoSmithKline (GSK)
   
   • Flagship Product: Fluarix Tetra.
     
   • Background: A well-established British pharmaceutical company; another traditional split-virion vaccine widely administered across private practices in Hong Kong.
     
5. AstraZeneca
   
   • Flagship Product: Fluenz Tetra (nasal spray live attenuated influenza vaccine).
     
   • Background: Provides an injection-free nasal spray option designed for needle-phobic children and adolescents (aged 2 to 49 years).
     

Vaccine Mechanisms and Formulations Deconstructed: Egg-Based vs. Recombinant Technology

Distinguishing between brands requires understanding their production processes and antigen purification technologies:
Plaintext

Influenza Vaccine Technology Pathways
├── Traditional Egg-Based Technology
│   ├── Split Virion Vaccines: Vaxigrip (Sanofi), Fluarix (GSK), Anfluvac (Sinovac)
│   └── Subunit Vaccines: Influvac (Abbott)
├── Recombinant Protein Technology (Egg-Free / Insect Cell Expression)
│   └── Recombinant Influenza Vaccine (RIV): Flublok (Sanofi)
└── Live Attenuated Virus Technology (Weakened Live Virus)
    └── Live Attenuated Influenza Vaccine (LAIV) Nasal Spray: Fluenz Tetra (AstraZeneca)

1. Traditional Egg-Based Split Virion Vaccines

• Representative Brands: Vaxigrip Tetra (Sanofi), Fluarix Tetra (GSK), Anfluvac (Sinovac)
  
• Composition & Mechanism: WHO-recommended virus strains are inoculated and cultured in embryonated chicken eggs. Following viral harvest, chemical agents inactivate the virus, and surfactants split the viral lipid envelope to extract key surface antigens, notably hemagglutinin (HA) and neuraminidase (NA).
  
• Key Features: Long clinical history, established manufacturing standards, and safety verified over billions of administered doses worldwide. While trace amounts of ovalbumin (egg protein) may remain, modern purification processes are sufficiently advanced that the vast majority of individuals with mild egg allergies (manifesting only as hives) can safely receive them.
  

2. Subunit Purified Vaccines

• Representative Brand: Influvac Tetra (Abbott)
  
• Composition & Mechanism: Also cultured and inactivated in chicken eggs. After viral disruption, the material undergoes precision ultrafiltration and purification to eliminate internal structural viral core proteins, isolating only purified surface antigens (HA and NA).
  
• Key Features: Contains fewer extraneous viral proteins, theoretically reducing non-specific immune stimulation. Clinically, it correlates with slightly lower rates of local erythema, induration, or low-grade post-vaccination fever compared to standard split-virion alternatives.
  

3. Recombinant Influenza Vaccine (RIV)

• Representative Brand: Flublok (produced and distributed by Sanofi)
  
• Composition & Mechanism: Completely avoids embryonated eggs and utilizes no live virus. Using the Baculovirus Expression Vector System (BEVS), the genetic sequence encoding influenza hemagglutinin is introduced into insect cell cultures (Spodoptera frugiperda cell line) to express and harvest purified HA protein at scale.
  
• Key Features:
  
  • 100% Egg-Free: The preferred choice for individuals with histories of severe egg allergy (anaphylaxis).
    
  • High Antigen Content: Standard inactivated vaccines contain 15 µg of HA per strain (totaling 45–60 µg), whereas recombinant formulations such as Flublok provide 45 µg of HA per strain (totaling approximately 135–180 µg)—a threefold increase in antigen concentration.
    
  • Enhanced Efficacy: Clinical trials demonstrate that among older demographics (aged 50 and above) experiencing immunosenescence, recombinant vaccines generate significantly higher antibody titers and offer superior protective efficacy over standard-dose vaccines.
    

4. Nasal Spray Live Attenuated Influenza Vaccine (LAIV)

• Representative Brand: Fluenz Tetra (AstraZeneca)
  
• Composition & Mechanism: Contains laboratory-attenuated, temperature-sensitive, low-pathogenicity live viruses. These viruses replicate minimally in the cooler mucosal environment of the nasal passages (around 32°C) but cannot replicate within the warmer lower respiratory tract (37°C).
  
• Key Features: Needle-free and non-invasive, eliciting mucosal IgA immunity directly at the primary port of viral entry. However, because it contains live attenuated viral particles, it is strictly contraindicated in pregnant women, immunocompromised individuals, and patients with severe asthma.
  

Comprehensive Comparison of Major Flu Vaccine Brands

Below is a summary of specifications, technologies, dosages, and eligible age ranges for mainstream brands distributed in Hong Kong:

In-Depth Safety and Side Effect Comparison

All influenza vaccines registered in Hong Kong must clear rigorous regulatory safety assessments. Severe allergic reactions remain exceedingly rare (approximately one in a million doses). Typical adverse event profiles across vaccine types include:

1. Local Injection Site Reactions

• Inactivated Vaccines (Vaxigrip, Influvac, Fluarix, Anfluvac): The most common complaints include local erythema, transient soreness, swelling, or mild induration at the injection site. These usually develop within several hours post-injection and resolve spontaneously within 1 to 2 days.
  
• Recombinant Vaccine (Flublok): Due to its 45 µg antigen payload (three times standard dosage), reported rates of local tenderness or redness may be slightly elevated relative to standard-dose vaccines, though the vast majority remain mild to moderate.
  
• Nasal Spray Vaccine (Fluenz): Completely eliminates injection-site discomfort, though a minority of recipients may experience temporary rhinorrhea, nasal congestion, or minor throat irritation.
  

2. Mild Systemic Reactions

• Sensitive individuals may experience transient low-grade fever (rarely exceeding 38.5°C), mild headaches, myalgia, or fatigue. This reflects standard physiological activation as the immune system encounters foreign antigens and synthesizes protective antibodies—it is not an active flu infection—and typically abates within 24 to 48 hours.
  

3. Rare Severe Adverse Event: Guillain-Barré Syndrome (GBS)

• Epidemiological surveillance indicates an exceptionally low risk of Guillain-Barré Syndrome (a rare peripheral demyelinating neuropathy) following influenza vaccination (roughly 1 to 2 cases per million doses administered). Clinical data consistently establish that the risk of developing GBS secondary to a severe wild-type influenza infection substantially outweighs the baseline risk associated with receiving the vaccine.
  

Expert Selection Guide: How Should Different Demographics Choose?

When assessing available brands and technologies, consider your age, clinical profile, and preferences:

1. Healthy Adults and Working Professionals:
   
   • Primary Recommendation: Standard-dose inactivated vaccines (e.g., Vaxigrip Tetra, Influvac Tetra, or Fluarix Tetra). High cost-effectiveness, widespread availability across private practices and government-subsidized networks, and dependable efficacy.
     
2. Seniors Aged 65+ and Immunosenescent Individuals:
   
   • Recommendation: Where clinic inventory and personal budget permit, prioritize high-antigen Flublok (recombinant vaccine) to stimulate higher neutralizing antibody titers. Alternatively, accessing standard inactivated vaccines (such as Vaxigrip) through subsidized or free public healthcare schemes continues to offer strong protection against severe disease and death.
     
3. Individuals with Severe Egg Allergies (Anaphylaxis):
   
   • Recommendation: Flublok is manufactured using recombinant DNA technology, contains zero ovalbumin, and is entirely safe. Where recombinant vaccines are unavailable, WHO and international guidelines permit the use of ultra-purified subunit or split-virion vaccines administered under physician observation in settings equipped with emergency resuscitation protocols.
     
4. Children and Adolescents (Aged 2 to 18) with Severe Needle Phobia:
   
   • Recommendation: Provided the individual has no personal history of asthma and is not immunocompromised, the needle-free Fluenz Tetra nasal spray offers a painless method to minimize injection-related resistance.
     
5. Pregnant and Breastfeeding Women:
   
   • Recommendation: Injectable inactivated influenza vaccines (Vaxigrip Tetra or Influvac Tetra). Extensive safety registries confirm inactivated vaccines are safe during all trimesters. In addition, transplacental and breastmilk transfer of maternal antibodies affords vital passive immunity to neonates throughout their initial 6 months of life. Pregnant women must not receive the live attenuated nasal spray vaccine.
     

Disclaimer

The medical and pharmaceutical information presented herein is intended solely for public health education and general informational purposes. It should not be construed as an individual medical diagnosis, therapeutic prescription, or clinical guidance. Vaccine indications, contraindications, and administration fees may vary based on personal physiological factors, medical history, and individual healthcare facility policies. Prior to receiving any influenza vaccine, please consult a registered medical practitioner or qualified healthcare provider and disclose your complete medical history and known drug allergies.

Authoritative Medical Sources and Links

1. Centre for Health Protection (CHP), Department of Health, Hong Kong – Frequently Asked Questions on Seasonal Influenza Vaccination
   https://www.chp.gov.hk/tc/features/100764.html
   
2. Centre for Health Protection (CHP), Department of Health, Hong Kong – "Flu Express" Surveillance Reports
   https://www.chp.gov.hk/tc/guideline/110518.html
   
3. World Health Organization (WHO) – Recommendations for Influenza Vaccine Composition Technical Documents
   https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations
   
4. US Centers for Disease Control and Prevention (CDC) – Influenza Vaccine Technology and Types Guidance
   https://www.cdc.gov/flu/prevent/different-flu-vaccines.htm
   
5. US Centers for Disease Control and Prevention (CDC) – Recombinant Influenza Vaccine Clinical Information
   https://www.cdc.gov/flu/prevent/qa_flublok-vaccine.htm
   
6. European Medicines Agency (EMA) – VaxigripTetra Summary of Product Characteristics (SmPC)
   https://www.ema.europa.eu/en/medicines/human/referrals/vaxigriptetra
   
7. European Medicines Agency (EMA) – Influvac Tetra Summary of Product Characteristics (SmPC)
   https://www.ema.europa.eu/en/medicines/human/referrals/influvac-tetra
   
8. National Health Service (NHS), UK – Flu Vaccine Types, Safety, and Side Effects
   https://www.nhs.uk/conditions/vaccinations/flu-influenza-vaccine/